Pizotifen

Pizotifen Market Outlook

The global Pizotifen market is projected to reach approximately USD 1.5 billion by 2033, exhibiting a CAGR of around 7.2% during the forecast period from 2025 to 2033. This growth can be attributed to the increasing prevalence of migraine disorders, which is compelling healthcare providers to adopt effective prophylactic treatments. Additionally, the rising awareness about the therapeutic benefits of Pizotifen for various ailments such as allergic conditions and appetite stimulation is expected to drive demand. There is also a growing trend towards personalized medicine, with Pizotifen being recognized for its efficacy in specialized patient populations. On the production side, advancements in manufacturing technology and processes are facilitating the production of high-quality Pizotifen formulations, further supporting market growth.

Growth Factor of the Market

The growth of the Pizotifen market is significantly influenced by the rising incidence of migraine and headache disorders globally, prompting healthcare systems to seek effective treatment options. Moreover, the expanding understanding of Pizotifen’s multi-faceted therapeutic applications, such as in allergic conditions and appetite stimulation, continues to broaden its market potential. Increasing investments in research and development are also propelling innovation in drug formulations, creating a more diverse range of Pizotifen products in the market. Additionally, the growing acceptance of online and e-pharmacy channels for drug distribution is making medications more accessible to patients, further stimulating demand. Furthermore, awareness campaigns and educational initiatives about migraine management are positively influencing patient demand, solidifying Pizotifen's role in modern therapeutic regimens.

Key Highlights of the Market

• The market is expected to witness a robust CAGR of 7.2% from 2025 to 2033.
• North America is projected to hold a significant market share, driven by advanced healthcare infrastructure and increasing migraine cases.
• Pizotifen tablets are expected to dominate the product type segment due to their ease of use and established efficacy.
• Retail pharmacies are anticipated to be the leading distribution channel, attributed to their widespread accessibility and patient preference.
• Research and innovation in drug formulations are expected to enhance the clinical applications of Pizotifen, fostering market expansion.

By Product Type

Tablets:

Pizotifen tablets represent the most popular product type in the market owing to their convenience and ease of administration. They are typically designed for daily use in migraine prophylaxis and have been well-received by both healthcare providers and patients. The stable dosage form allows for precise dosing, which is critical for managing chronic conditions such as migraines. Furthermore, the long shelf life of tablets compared to other forms, like syrups or injections, adds to their appeal for consumers and healthcare providers alike. Educational initiatives promoting adherence to oral medication regimens further support the growth of this segment.

Syrup:

Pizotifen syrup is gaining traction, particularly in pediatric and geriatric populations who may have difficulty swallowing tablets. The liquid formulation allows for flexible dosing, which can be tailored according to individual patient needs. Syrups often come with flavoring agents to improve palatability, making them more acceptable for children and those with specific dietary requirements. This form is particularly useful in managing allergic conditions and appetite stimulation where precise dosage adjustments may be necessary, thereby broadening its therapeutic use. The syrup segment is expected to grow as healthcare providers continue to advocate for accessible treatment options for vulnerable populations.

Injection:

Pizotifen injections are less common but are utilized in specific clinical scenarios where rapid pharmacological action is required. This route of administration can provide immediate therapeutic effects, making it an option for patients who may experience severe acute migraine attacks. While the market for injections is currently limited due to factors such as patient discomfort and the need for skilled personnel for administration, it still holds potential for growth in specialized healthcare settings like hospitals and clinics. Research into new injection delivery methods, such as auto-injectors, could enhance patient comfort and compliance, thereby stimulating market interests in this segment.

Capsules:

Capsules are another formulation of Pizotifen that offer advantages such as taste masking and protection of sensitive ingredients from degradation. Although they are not as widely used as tablets, capsules can provide a more elegant dosage form that appeals to certain patient populations. The encapsulation technology allows for the combination of multiple active ingredients in one dosage form, catering to patients with complex treatment regimens. The capsule segment is expected to see incremental growth as more patients seek alternatives to conventional tablets, particularly among individuals who prefer the swallowing experience of capsules over tablets.

Suspensions:

Pizotifen suspensions are primarily used in pediatric care, offering an alternative for children who cannot take solid dosage forms. This formulation enables precise dosing, allowing healthcare providers to tailor treatments effectively for young patients. The market for suspensions is expected to grow as the focus on pediatric health continues to rise, and as healthcare systems strive for comprehensive management of migraine and allergic conditions in children. The ability to provide a liquid medication that can be easily adjusted according to the child’s weight and age enhances the usability of suspensions in clinical practice.

By Application

Migraine Prophylaxis:

Migraine prophylaxis accounts for a significant share of the Pizotifen market, driven by the high prevalence of migraines worldwide. As healthcare systems increasingly recognize the impact of migraines on quality of life, there is growing emphasis on preventive treatments. Pizotifen is clinically proven to reduce the frequency and severity of migraine attacks, leading to improved patient outcomes and satisfaction. The segment is expected to grow as more patients are diagnosed and treated for migraines, and as providers adopt Pizotifen as a first-line option in managing chronic migraine patients.

Allergic Conditions:

Pizotifen is also utilized in treating various allergic conditions, including allergic rhinitis and chronic urticaria. The drug's antihistaminic properties make it effective at alleviating symptoms associated with allergies, providing relief to a significant patient population. This application supports the market growth as a broader awareness of allergic conditions and their management increases globally. As patients continually seek effective treatments for allergy symptoms, the demand for Pizotifen in this application is expected to rise, solidifying its role as a multipurpose therapeutic agent.

Appetite Stimulation:

Appetite stimulation is another important application of Pizotifen, particularly in patients with conditions that lead to decreased appetite, such as cancer, chronic illnesses, or anorexia. The drug has gained recognition for its effectiveness in enhancing appetite among these vulnerable populations. As the healthcare sector places increased focus on nutrition and dietary health, the demand for appetite stimulants such as Pizotifen is expected to grow, providing essential support to improve patient outcomes. The expansion of this application reflects ongoing changes in treatment paradigms towards holistic patient care.

Others:

Other applications of Pizotifen include its use in managing conditions like tension-type headaches and insomnia. While these applications may not dominate the market, they contribute to the drug's versatility and overall demand. The ability to address multiple conditions increases the relevance of Pizotifen in various therapeutic settings, encouraging healthcare providers to consider it for a wider range of patients. Ongoing research may uncover additional uses for Pizotifen, potentially expanding its market presence even further in the coming years.

By Distribution Channel

Hospitals:

Hospitals serve as a critical distribution channel for Pizotifen due to their comprehensive patient care services and the increasing number of patients seeking treatment for migraine and related conditions. Hospitals often have the infrastructure to provide specialized care, including inpatient and outpatient services, which may include administration of Pizotifen in various formulations. The collaboration between hospitals and pharmaceutical companies is expected to strengthen, as hospitals require consistent supplies of effective medications to manage their patient populations. The growth of this channel is anticipated to continue as hospitals adapt to an evolving landscape of patient needs and treatment protocols.

Retail Pharmacies:

Retail pharmacies represent one of the most significant distribution channels for Pizotifen, providing easy accessibility for patients to obtain their medications without needing a hospital visit. As the number of retail pharmacy chains expands, so does the availability of Pizotifen and related products. This channel plays a crucial role in patient adherence to prescribed treatments, as patients can easily refill prescriptions and seek advice from pharmacists. Retail pharmacies are expected to thrive in the market as they increasingly integrate digital technologies, such as online ordering and delivery services, to cater to changing consumer preferences.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel in recent years due to the convenience and accessibility they offer. Patients are increasingly turning to digital platforms to order their medications, including Pizotifen, particularly during the COVID-19 pandemic. The online pharmacy sector is expected to grow as consumers prioritize ease of access and delivery options. Regulatory changes allowing more medications to be dispensed online are further promoting this channel's expansion. Online pharmacies are not only catering to urban populations but also bridging gaps in rural areas where access to physical pharmacies may be limited, thus expanding the market reach of Pizotifen.

Drug Stores:

Drug stores remain an essential distribution channel for Pizotifen, serving localized markets and providing patients with a trusted source for their medications. These establishments often combine pharmacy services with general retail, allowing consumers to purchase OTC products alongside prescription medications. The presence of knowledgeable staff in drug stores enables personalized consultations, which can enhance patient trust and satisfaction. As drug stores continue to adapt their service offerings to meet patient needs and preferences, they will play an integral role in the ongoing distribution of Pizotifen.

Others:

The "Others" category encompasses various distribution channels that contribute to the Pizotifen market, including specialty pharmacies and institutional pharmacies. Specialty pharmacies are dedicated to managing complex and chronic conditions, providing tailored services to patients requiring specialized medications. Institutional pharmacies, often tied to healthcare facilities, ensure that patients in long-term care or rehabilitation settings have access to necessary treatments, including Pizotifen. As the healthcare landscape evolves, these alternative distribution channels will continue to support the overall accessibility of Pizotifen and foster its market growth.

By Ingredient Type

Pizotifen Malate:

Pizotifen malate is one of the primary ingredient types used in the formulation of Pizotifen medications. It is known for its effectiveness in controlling migraine attacks and is the most commonly prescribed form. The robust clinical data supporting its efficacy and safety profile contributes to its widespread use in both tablets and syrup formulations. As healthcare providers increasingly rely on evidence-based treatments for migraine prophylaxis, the demand for Pizotifen malate will likely continue to grow, solidifying its position within the ingredient landscape.

Pizotifen Hydrogen Malate:

Pizotifen hydrogen malate is another formulation of Pizotifen that is gaining traction within the market. Its unique properties may offer advantages in terms of bioavailability and stability, making it an appealing alternative to traditional Pizotifen malate formulations. Ongoing research and development efforts to optimize formulations containing Pizotifen hydrogen malate could further enhance its presence in the market. As more studies emerge demonstrating the benefits of this ingredient type, it is poised to capture attention from both manufacturers and healthcare providers alike.

Pizotifen Citrate:

Pizotifen citrate represents a niche ingredient type in the Pizotifen market, offering potential differentiation for manufacturers. While not as widely utilized as Pizotifen malate, the citrate formulation may provide unique stability and solubility characteristics that enhance product appeal. As competition in the Pizotifen market intensifies, exploring alternative ingredient types like Pizotifen citrate may allow manufacturers to differentiate their products and cater to specific patient populations or preferences. Continued innovation and formulation advancements will be crucial for maximizing the potential of Pizotifen citrate in the market.

Pizotifen Acetate:

Pizotifen acetate is another ingredient type that may find its applications within the Pizotifen market, albeit on a smaller scale. Its distinct formulation may be leveraged in specialized scenarios where other ingredient types are less effective. As research into Pizotifen acetate continues to evolve, more insights into its therapeutic benefits will likely emerge. The growing focus on personalized medicine may lead to increased interest in Pizotifen acetate formulations tailored to individual patient needs, potentially expanding its market presence moving forward.

Others:

The "Others" category includes various other ingredient forms that may be utilized in the production of Pizotifen. While these ingredient types may not dominate the market, they provide essential alternatives for manufacturers looking to innovate and diversify their product offerings. As consumer preferences shift towards more personalized and targeted treatments, the exploration of additional ingredient types could play a key role in enhancing Pizotifen’s therapeutic landscape. Ongoing research and development efforts will be vital for identifying and validating the potential benefits of these alternative ingredient types.

By Region

The North American Pizotifen market is projected to hold a significant share, driven by an advanced healthcare infrastructure and an increasing prevalence of migraine disorders. The region is expected to grow at a CAGR of 7.5%, reflecting a growing awareness of migraine treatments among both healthcare professionals and patients. The combination of a substantial patient base, effective marketing strategies, and the presence of key pharmaceutical players contributes to North America’s dominance. Furthermore, the regulatory environment in this region supports the continuous introduction of innovative Pizotifen products into the marketplace, further solidifying its growth prospects.

Europe is another critical region for the Pizotifen market, characterized by high healthcare expenditure and a proactive approach towards managing chronic conditions such as migraines. The European market is anticipated to exhibit steady growth, with countries like Germany and France leading the charge due to their robust healthcare systems and high demand for effective migraine prophylaxis. The increasing focus on patient-centered care and personalized treatment options is expected to foster innovation and drive market developments in this region. As healthcare providers continue to prescribe Pizotifen for a range of applications, the European segment is positioned for sustained growth in the coming years.

Opportunities

The Pizotifen market is poised for significant growth, presenting numerous opportunities for stakeholders engaged in the pharmaceutical industry. As the understanding of migraine disorders expands, healthcare providers are increasingly seeking effective treatment options for patients struggling with chronic headaches. The ongoing research into the multifaceted therapeutic benefits of Pizotifen provides opportunities for the development of new formulations and applications. Increased investment in clinical trials exploring the efficacy of Pizotifen in various conditions opens new avenues for market penetration, particularly in areas such as pediatric care, where demand for effective treatments is growing. Additionally, the rise in telemedicine and digital health solutions presents a unique opportunity for online pharmacy services to broaden their market reach, facilitating easier access to Pizotifen for patients.

Another promising opportunity lies in the growing emphasis on personalized medicine, which is reshaping treatment paradigms in healthcare. By tailoring Pizotifen treatments to individual patient needs, manufacturers can enhance therapeutic outcomes and patient satisfaction, leading to increased loyalty and market share. Collaborations between pharmaceutical companies and academic institutions can foster innovation, as joint research efforts may lead to the discovery of new therapeutic uses for Pizotifen. Furthermore, expanding distribution channels, such as online pharmacies and specialty drug stores, will increase accessibility and convenience for patients, ultimately driving growth in the Pizotifen market.

Threats

Despite its promising growth prospects, the Pizotifen market faces several threats that may hinder its expansion. One significant challenge is the intense competition from alternative migraine prophylaxis medications and therapies. Numerous pharmaceutical companies are developing and marketing other treatments that may offer similar or improved efficacy, posing a threat to Pizotifen's market share. Additionally, patent expirations and the introduction of generic alternatives could lead to price erosion, impacting the profitability of existing products. Regulatory hurdles and changes in healthcare policies may also present obstacles for manufacturers attempting to bring new formulations or applications of Pizotifen to market. These factors necessitate continuous innovation and strategic planning to navigate the competitive landscape effectively.

Another potential threat to the Pizotifen market is the growing skepticism among patients regarding the efficacy of pharmaceutical treatments. The increasing preference for holistic and natural remedies could shift consumer behavior away from conventional medications, including Pizotifen. As patients seek alternative approaches to manage symptoms, the demand for traditional pharmaceuticals may decline, impacting overall market growth. Moreover, misinformation surrounding migraine treatment options could further complicate the market landscape, making it essential for manufacturers to invest in education and awareness campaigns to counteract negative perceptions and promote the benefits of Pizotifen.

Competitor Outlook

• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Mylan N.V.
• Hikma Pharmaceuticals PLC
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Roche Holding AG
• Dr. Reddy's Laboratories Ltd.
• Almirall S.A.
• Glenmark Pharmaceuticals Ltd.
• Helsinn Healthcare S.A.
• Sanofi S.A.
• Zydus Cadila
• Hetero Labs Limited

The competitive landscape of the Pizotifen market is characterized by a mix of established pharmaceutical giants and emerging players striving to capture market share through innovative products and formulations. Major companies such as Novartis AG and Pfizer Inc. continue to dominate the market due to their strong portfolios, well-established distribution networks, and substantial investments in research and development. These companies leverage their resources to continuously improve Pizotifen formulations and explore new therapeutic applications, ensuring their position at the forefront of the market.

In addition to pharmaceutical behemoths, mid-sized firms like Teva Pharmaceutical Industries Ltd. and Mylan N.V. are making significant strides by offering competitive pricing and developing generic versions of Pizotifen. These generic formulations cater to a broader consumer base and appeal to cost-sensitive patients, thereby enhancing market penetration. Meanwhile, companies like Dr. Reddy's Laboratories and Aurobindo Pharma are also focusing on innovation and diversification of their product offerings to remain competitive in this dynamic landscape.

Emerging players in the Pizotifen market are identifying niche opportunities to differentiate themselves from traditional competitors. Firms like Glenmark Pharmaceuticals and Hetero Labs Limited are focusing on targeted therapies in specific patient populations, leveraging their agility to adapt to changing market demands. As the focus shifts towards personalized medicine, these companies are well-positioned to capitalize on the growing need for customized treatments that address individual patient needs. Collaborations with healthcare providers and academic institutions can further enhance the innovation pipeline for these smaller entities, enabling them to remain competitive in this evolving market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Mylan N.V.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Zydus Cadila
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Almirall S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Hetero Labs Limited
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Aurobindo Pharma Ltd.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Helsinn Healthcare S.A.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hikma Pharmaceuticals PLC
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Dr. Reddy's Laboratories Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Glenmark Pharmaceuticals Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Pizotifen Market, By Application
    • 6.1.1 Migraine Prophylaxis
    • 6.1.2 Allergic Conditions
    • 6.1.3 Appetite Stimulation
    • 6.1.4 Others
  • 6.2 Pizotifen Market, By Product Type
    • 6.2.1 Tablets
    • 6.2.2 Syrup
    • 6.2.3 Injection
    • 6.2.4 Capsules
    • 6.2.5 Suspensions
  • 6.3 Pizotifen Market, By Ingredient Type
    • 6.3.1 Pizotifen Malate
    • 6.3.2 Pizotifen Hydrogen Malate
    • 6.3.3 Pizotifen Citrate
    • 6.3.4 Pizotifen Acetate
    • 6.3.5 Others
  • 6.4 Pizotifen Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Pizotifen Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Pizotifen market is categorized based on

By Product Type

• Tablets
• Syrup
• Injection
• Capsules
• Suspensions

By Application

• Migraine Prophylaxis
• Allergic Conditions
• Appetite Stimulation
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Others

By Ingredient Type

• Pizotifen Malate
• Pizotifen Hydrogen Malate
• Pizotifen Citrate
• Pizotifen Acetate
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Mylan N.V.
• Hikma Pharmaceuticals PLC
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Roche Holding AG
• Dr. Reddy's Laboratories Ltd.
• Almirall S.A.
• Glenmark Pharmaceuticals Ltd.
• Helsinn Healthcare S.A.
• Sanofi S.A.
• Zydus Cadila
• Hetero Labs Limited